Skip to content

Study · Randomized controlled trial · n = 62 · 2014

3 results

Preoperative octreotide treatment of acromegaly: long-term results of a randomised controlled trial.

Fougner SL, Bollerslev J, Svartberg J, Øksnes M, Cooper J, Carlsen SM

European journal of endocrinology27 May 2014Cited by 49 (Europe PMC)

PMID24866574 (opens in a new tab)DOI10.1530/eje-14-0249 (opens in a new tab)PepBankPUB-24866574
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In acromegaly, postoperative treatment proportions were equal after octreotide pretreatment and direct surgery.

    In plain wordsIn acromegaly, postoperative treatment was equally frequent after octreotide pretreatment and direct surgery.

    Peptide
    Octreotide
    Outcome
    No significant changePostoperative acromegaly treatment
    Study

    n = 62

    Comparator
    Direct surgery
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    The proportion of patients receiving post-operative acromegaly treatment was equal in the two groups.
    2 context sentences
    Summary · context
    Newly diagnosed patients were randomised to direct surgery (n=30) or 6-month pretreatment with octreotide LAR (n=32).
    Summary · context
    Cure was defined as normal IGF1 levels and by normal IGF1 level combined with nadir GH <2 mU/l in an oral glucose tolerance test, all without additional post-operative treatment.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In acromegaly macroadenomas, cure by the combined criteria at 1 postoperative year was 10/26 (38%) after octreotide pretreatment versus 6/25 (24%) after direct surgery (P=0.27).

    In plain wordsIn acromegaly macroadenomas, cure was numerically higher after octreotide pretreatment than direct surgery at one postoperative year.

    Peptide
    Octreotide
    Outcome
    IncreaseMacroadenoma cure at one postoperative year
    Study

    n = 51

    Comparator
    Direct surgery
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Cure rate
    38%
    octreotide pretreatment, 10 of 26
    Cure rate
    24%
    direct surgery, 6 of 25
    P value
    0.27
    1 year(s) postoperatively

    Source sentences

    Summary
    When using the combined criteria for cure, 10/26 (38%) macroadenomas were cured in the pretreatment group compared with 6/25 (24%) in the direct surgery group 1 year postoperatively (P=0.27), and 9/22 (41%) vs 6/22 (27%) macroadenomas, respectively, 5 years postoperatively (P=0.34).
    2 context sentences
    Summary · context
    Newly diagnosed patients were randomised to direct surgery (n=30) or 6-month pretreatment with octreotide LAR (n=32).
    Summary · context
    Cure was defined as normal IGF1 levels and by normal IGF1 level combined with nadir GH <2 mU/l in an oral glucose tolerance test, all without additional post-operative treatment.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In acromegaly macroadenomas, cure by the combined criteria at 5 postoperative years was 9/22 (41%) after octreotide pretreatment versus 6/22 (27%) after direct surgery (P=0.34).

    In plain wordsIn acromegaly macroadenomas, cure was numerically higher after octreotide pretreatment than direct surgery at five postoperative years.

    Peptide
    Octreotide
    Outcome
    IncreaseMacroadenoma cure at five postoperative years
    Study

    n = 44

    Comparator
    Direct surgery
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Cure rate
    41%
    octreotide pretreatment, 9 of 22
    Cure rate
    27%
    direct surgery, 6 of 22
    P value
    0.34
    5 year(s) postoperatively

    Source sentences

    Summary
    When using the combined criteria for cure, 10/26 (38%) macroadenomas were cured in the pretreatment group compared with 6/25 (24%) in the direct surgery group 1 year postoperatively (P=0.27), and 9/22 (41%) vs 6/22 (27%) macroadenomas, respectively, 5 years postoperatively (P=0.34).
    2 context sentences
    Summary · context
    Newly diagnosed patients were randomised to direct surgery (n=30) or 6-month pretreatment with octreotide LAR (n=32).
    Summary · context
    Cure was defined as normal IGF1 levels and by normal IGF1 level combined with nadir GH <2 mU/l in an oral glucose tolerance test, all without additional post-operative treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT00521300

Preoperative Octreotide Treatment of Acromegaly

St. Olavs Hospitaln = 62Sept 1999 to May 2010

Acromegaly

Trial pageClinicalTrials.govUpdated 2 Jun 2014

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.